What are the pharmacokinetics of chemokine receptor antagonists in antiretroviral therapy of HIV infection?

Updated: Apr 18, 2019
  • Author: R Chris Rathbun, PharmD, BCPS (AQ-ID), AAHIVP; Chief Editor: John Bartlett, MD  more...
  • Print


Maraviroc is approximately 75% protein-bound, primarily to albumin and alpha1 acid glycoprotein. Its terminal half-life is 15-30 hours. Maraviroc is metabolized through CYP3A4 and is a substrate for the efflux pump p-glycoprotein. Dosage adjustment is required when maraviroc is administered in combination with potent inhibitors or inducers of CYP3A4 (see Drug Interactions with Antiretroviral Therapy or DHHS Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents). [97, 8]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!